Some of its best-selling drugs, including migraine pill Imitrex and anti-depressant Paxil, are on track to lose patent protection. ...
Five of the company's best-selling medicines will lose patent protection this year, including the migraine pill Imitrex and antidepressants Wellbutrin XL ...
The tablets by the company are generic equivalents of GlaxoSmithKline's Imitrex tablets widely prescribed in the US. It is used specifically for treating ...
GSK had settled patent litigations with Ranbaxy Laboratories and Dr Reddy’s Laboratories over manufacturing generic versions of Imitrex. ...
Sumatriptan succinate tablets are the generic equivalent of GlaxoSmithKline's Imitrex(R) tablets, which are indicated for the treatment of acute migraines.
all 6 news articles
We expect to benefit from the upside potential from the launch of Sumatriptan (GSK's Imitrex) in the US in third quarter of 2008. ...
Also this past week, Ranbaxy Laboratories announced it had settled matters relating to possible patent litigation with GlaxoSmithKline (GSK) over Imitrex ...
According to IMS figures, Imitrex had annual sales of $985 million in 2007, a Ranbaxy Laboratories release said. Other details of the settlement were not ...
... it reached a settlement with British drug maker GlaxoSmithKline over possible patent litigation regarding a generic version of Glaxo's Imitrex tablets. ...